INTRODUCTION: The effects of pancreatic polypeptide (PP) infusion were examined in patients on insulin pump therapy to determine whether PP administration can reduce insulin requirements in patients with type 1 diabetes mellitus (T1DM) or type 3c diabetes mellitus (T3cDM; pancreatogenic). METHODS:Ten subjects with long-standing T1DM (n = 7) or T3cDM (n = 3) on insulin pump treatment received a 72 h subcutaneous infusion of 2 pmol/kg/min bovine PP or saline by portable infusion pump in a single-blinded, randomized, crossover design. RESULTS: Pancreatic polypeptide infusion raised plasma PP levels to 450-700 pmol/liter. Daily insulin infusion requirements (I) fell from 48 ± 6.9 to 40 ± 7.5 U on day 2 (p < .05) and from 46 ± 7.7 to 37 ± 6.6 U on day 3 (p < .05) of PP infusion compared with saline. Corrected for average blood glucose concentration (G), I/G fell in 10/10 subjects during the second 24 h period and in 7/10 subjects during the third 24 h period; sensitivity to insulin, calculated as 1/(I/G), increased 45% ± 12% on day 2 (p < .01) and 34% ± 14% on day 3 (p < .05) of PP infusion. Pancreatic polypeptide responses to a test meal were compared with the change in insulin infusion requirements in 5 subjects; the reduction in insulin requirements seen during PP infusion correlated with the degree of baseline PP deficiency (p < .002). CONCLUSIONS: A concurrent subcutaneous infusion of PP enhances insulin sensitivity and reduces insulin requirements in patients with long-standing T1DM and T3cDM on insulin pump therapy. The benefit of PP infusion correlated with the degree of PP deficiency.
RCT Entities:
INTRODUCTION: The effects of pancreatic polypeptide (PP) infusion were examined in patients on insulin pump therapy to determine whether PP administration can reduce insulin requirements in patients with type 1 diabetes mellitus (T1DM) or type 3c diabetes mellitus (T3cDM; pancreatogenic). METHODS: Ten subjects with long-standing T1DM (n = 7) or T3cDM (n = 3) on insulin pump treatment received a 72 h subcutaneous infusion of 2 pmol/kg/min bovinePP or saline by portable infusion pump in a single-blinded, randomized, crossover design. RESULTS:Pancreatic polypeptide infusion raised plasma PP levels to 450-700 pmol/liter. Daily insulin infusion requirements (I) fell from 48 ± 6.9 to 40 ± 7.5 U on day 2 (p < .05) and from 46 ± 7.7 to 37 ± 6.6 U on day 3 (p < .05) of PP infusion compared with saline. Corrected for average blood glucose concentration (G), I/G fell in 10/10 subjects during the second 24 h period and in 7/10 subjects during the third 24 h period; sensitivity to insulin, calculated as 1/(I/G), increased 45% ± 12% on day 2 (p < .01) and 34% ± 14% on day 3 (p < .05) of PP infusion. Pancreatic polypeptide responses to a test meal were compared with the change in insulin infusion requirements in 5 subjects; the reduction in insulin requirements seen during PP infusion correlated with the degree of baseline PP deficiency (p < .002). CONCLUSIONS: A concurrent subcutaneous infusion of PP enhances insulin sensitivity and reduces insulin requirements in patients with long-standing T1DM and T3cDM on insulin pump therapy. The benefit of PP infusion correlated with the degree of PP deficiency.
Authors: N E Seymour; F C Brunicardi; R L Chaiken; H E Lebovitz; R E Chance; R L Gingerich; D Elahi; D K Andersen Journal: Surgery Date: 1988-08 Impact factor: 3.982
Authors: Y S Sun; F C Brunicardi; P Druck; S Walfisch; S A Berlin; R E Chance; R L Gingerich; D Elahi; D K Andersen Journal: Am J Surg Date: 1986-01 Impact factor: 2.565
Authors: K Inoue; T Tobe; T Suzuki; R Hosotani; M Kogire; A Fuchigami; T Miyashita; K Tsuda; Y Seino Journal: Ann Surg Date: 1987-08 Impact factor: 12.969
Authors: R Nosadini; S del Prato; A Tiengo; E Duner; G Toffolo; C Cobelli; P P Faronato; P Moghetti; M Muggeo Journal: Diabetes Date: 1982-04 Impact factor: 9.461
Authors: Michael R Rickels; Melena Bellin; Frederico G S Toledo; R Paul Robertson; Dana K Andersen; Suresh T Chari; Randall Brand; Luca Frulloni; Michelle A Anderson; David C Whitcomb Journal: Pancreatology Date: 2013-05-17 Impact factor: 3.996
Authors: Phil A Hart; Melena D Bellin; Dana K Andersen; David Bradley; Zobeida Cruz-Monserrate; Christopher E Forsmark; Mark O Goodarzi; Aida Habtezion; Murray Korc; Yogish C Kudva; Stephen J Pandol; Dhiraj Yadav; Suresh T Chari Journal: Lancet Gastroenterol Hepatol Date: 2016-10-12
Authors: Aliye Uc; Dana K Andersen; Melena D Bellin; Jason I Bruce; Asbjørn M Drewes; John F Engelhardt; Christopher E Forsmark; Markus M Lerch; Mark E Lowe; Brent A Neuschwander-Tetri; Stephen J OʼKeefe; Tonya M Palermo; Pankaj Pasricha; Ashok K Saluja; Vikesh K Singh; Eva M Szigethy; David C Whitcomb; Dhiraj Yadav; Darwin L Conwell Journal: Pancreas Date: 2016-11 Impact factor: 3.327
Authors: Dana K Andersen; Åke Andren-Sandberg; Eric J Duell; Michael Goggins; Murray Korc; Gloria M Petersen; Jill P Smith; David C Whitcomb Journal: Pancreas Date: 2013-11 Impact factor: 3.327
Authors: Siddamma Amoghimath; R N Suresha; M K Jayanthi; S L Shruthi; Ps Vaibhavi; A M Satish; V H Pushpa; H L Kalabharathi Journal: J Clin Diagn Res Date: 2015-01-01
Authors: Phil A Hart; Dana K Andersen; Kieren J Mather; Alicia C Castonguay; Mandeep Bajaj; Melena D Bellin; David Bradley; Noemy Contreras; Aida Habtezion; Murray Korc; Yogish Kudva; Maxim S Petrov; David C Whitcomb; Dhiraj Yadav; Ying Yuan; Jo Ann S Rinaudo; Sudhir Srivastava; Jose Serrano; Mark O Goodarzi Journal: Pancreas Date: 2018 Nov/Dec Impact factor: 3.327
Authors: Kendall R McEachron; Yi Yang; James S Hodges; Gregory J Beilman; Timothy L Pruett; Varvara A Kirchner; Ty B Dunn; Martin L Freeman; Guru Trikudanathan; Kristine E Mulier; Peggy Ptacek; Melena D Bellin Journal: Pancreas Date: 2020-07 Impact factor: 3.243